--- title: "Detailing and sample spend produced no prescribing lift" description: "A large share of rep detailing and samples went to HCPs whose prescribing never moved. Marketing & margin audit: $64k/yr in wasted spend cut." url: https://marginfix.ai/cases/detailing-and-sample-spend-produced-no-prescribing-lift/ lastmod: 2026-10-12 --- Detailing and sample spend produced no prescribing lift. [Request an audit →](/book/) Pharma · Generics # Detailing and sample spend produced no prescribing lift. This marketing & margin audit identified **$64k in wasted annual spend** in a Pharma business, evidenced, senior reviewed, and delivered in 7 days. $3–8M annual revenue Generics Focus: Detailing ROI −$64k wasted spend cut / yr 28% no lift detailing (before) 7 days to findings Detailing spend that moved no prescribing Before audit 28% → After fix 4% ## The business A generics manufacturer ran a large field force detailing HCPs and distributing samples, a traditional and expensive part of its commercial model. Coverage was broad and activity metrics looked healthy, so which HCPs the detailing and samples actually moved, and which received the same investment with no change in prescribing, was never rigorously analyzed. ## What triggered the audit Detailing and sample spend was substantial, yet prescribing growth didn’t obviously track it, hinting much of the effort landed on HCPs it never moved. The audit matched detailing and sample investment per HCP against actual prescribing change, testing where the spend genuinely drove lift. ## What the audit found A large share of the detailing and sample budget was producing no prescribing lift at all. Matching investment to outcomes HCP by HCP showed that the field force was allocated by broad coverage targets rather than by responsiveness, so a significant segment of physicians received regular visits and samples while their prescribing didn’t move at all. Either because they were already loyal, structurally unreachable, or simply unresponsive to detailing. Because the model measured reach and activity rather than prescribing change, this dead weight effort was invisible, and the same expensive investment kept flowing to nonresponders year after year. Reallocated away from them, the no lift detailing and samples represented roughly $64k a year of wasted commercial spend. ◉ How we produced this finding MarginFix pressure tested the Detailing ROI finding the same way it does for every pharma client: isolate what the spend actually caused, strip out what it merely took credit for, and let a named senior auditor validate the read against real data before a single figure is presented. Data sources: Spend by channel, campaign, creative and audience, joined to conversion and revenue data, plus a geo holdout test built to isolate what Detailing ROI genuinely caused rather than what it merely claimed. Key frameworks: Geo holdout incrementality testing, Marketing Mix Modeling (MMM) and attribution correction and inflation factor analysis, cross checked against Analytic Partners ROI Genome, Google Meridian and Meta Robyn. Human validation gate: Every incrementality read is rerun against your own data and signed off by a named senior auditor before it ships. No automated output ever leaves the building unreviewed. Verified against CRM / rep call logs Sample distribution records Territory spend ledger Finance P&L The wasted spend cut / yr was measured like for like over a matched period, reconciled to territory spend in the finance ledger, and signed off by a named senior auditor before publication. Client identity redacted to protect their commercial position. WORKING PAPER ████████ Generics Representative Redacted HCP segment Spend with no Rx lift High decile HCPs 4% Mid decile HCPs 14% Low decile HCPs 28% wasted spend cut / yr +$64,290 Recurring, recovered every year the fix holds, not a one off. Working paper: detailing spend that moved no prescribing traced line by line and reconciled to territory spend in the finance ledger over a matched period. Line items representative and redacted; the recovered figure is the reconciled audit finding. ## What we changed ✓ Matched detailing and sample investment to actual prescribing change per HCP, exposing exactly which physicians the expensive effort never moved. ✓ Reallocated field force time and samples away from nonresponders and toward the HCPs where detailing genuinely drives prescribing lift. ✓ Set coverage targets by responsiveness rather than broad reach, so the most expensive commercial effort follows measurable impact. ✓ Made prescribing lift per detailing dollar a monitored metric, so no lift spend can’t quietly persist across the field force season after season the way it had for years. ## The result The published chart shows detailing spend that produced no prescribing lift falling from 28% to 4%, a 24 percentage point decrease. The published material does not state the attribution method or measurement period behind that classification. $64k a year recovered by directing detailing and samples to the HCPs it actually moves, an annual figure equal to 11× the $5,950 Audit + Sprint fee. For any pharma commercial team, activity metrics are the trap: reach and call counts look healthy while a large slice of expensive effort lands on physicians it never influences. If you measure coverage rather than prescribing lift, you’re likely detailing nonresponders year after year. It takes matching investment to prescribing change to see it. A fixed fee audit does that in days. From kickoff to signed off findings: 7 days. ![Portrait photograph of Leslie Martin](/assets/team/leslie-martin.jpg) Reviewed & signed off by: Leslie Martin Senior Auditor · MarginFix · 10+ years of auditing experience ✓ Anonymized to protect the client · senior reviewed findings · Published June 8, 2025 · Last reviewed October 12, 2026 ## What the client said PHARMA Approved Jun 2025 $64k a year of wasted spend cut in 7 days Detailing spend that moved no prescribing: **28% → 4%** “Reach and call counts looked healthy. Leslie matched detailing and samples to prescribing change per HCP, and 28% of the effort landed on physicians it never moved. Field time now follows responsiveness, not coverage targets.” **Head of Commercial Operations · Pharma · Generics** Written approval Under NDA 7 days to findings ![Portrait photograph of Leslie Martin](/assets/team/leslie-martin.jpg) **Leslie Martin** Senior Auditor · signed this audit off [Request an audit →](/book/) [Prefer to talk it through first? Talk to an auditor →](/book/call/) ## More Pharma findings [Media ran outside the eligible population windows, −$58k/yr](/cases/media-ran-outside-the-eligible-population-windows/) [Retail vet channel discounts were set below margin, +$49k/yr](/cases/retail-vet-channel-discounts-were-set-below-margin/) [Patient acquisition spend ran above what reimbursement paid, −$71k/yr](/cases/patient-acquisition-spend-ran-above-what-reimbursement-paid/) [Congress and KOL sponsorship showed no measurable return, $88k/yr](/cases/congress-and-kol-sponsorship-showed-no-measurable-return/) [Seasonal media weight ignored when the category actually converted, +$60k/yr](/cases/seasonal-media-weight-ignored-when-the-category-actually-con/) [Unbranded search was paying for traffic the brand site already won, −$78k/yr](/cases/unbranded-search-was-paying-for-traffic-the-brand-site-alrea/) [The benchmark: what audits recover across 74 cases →](/benchmark/) [All case studies](/case-studies/) [Model a Pharma budget in the wasted ad spend calculator →](/estimator/pharma/)